



Express Mail No.: EV473971064US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|                 |   |                     |                  |
|-----------------|---|---------------------|------------------|
| Application of: | Srivastava et al.   | Confirmation No.:   | 1804             |
| Serial No.:     | 09/668,724  | Art Unit:           | 1642             |
| Filed:          | September 22, 2000  | Examiner:           | Reddig, Peter J. |
| For:            | ALPHA (2) MACROGLOBULIN<br>RECEPTOR AS A HEAT SHOCK<br>PROTEIN RECEPTOR AND USES<br>THEREOF | Attorney Docket No: | 8449-128-999     |

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56 AND 1.97**

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to references **A14 and A15 and C115 to C122** listed on the attached List of References Cited by Applicants.

Copies of references **A14 and C115 to C122** are submitted herewith. A copy of reference **A15** is not submitted herewith because it is a U.S. patent. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application. Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Pursuant to 37 C.F.R. §1.97(b), since it is believed that this information disclosure statement is being filed after the mailing date of a first Office Action on the merits, a fee of \$180.00 is believed to be due in connection herewith. Please charge the required fee to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date March 21, 2007

Adriane M. Antler 32,605  
Adriane M. Antler (Reg. No.)

JONES DAY  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939

Enclosure



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.

8449-128-999

APPLICATION NO.

09/668,724

APPLICANT

Srivastava et al.

FILING DATE

September 22, 2000

ART UNIT

1642

**U.S. PATENT DOCUMENTS**

| *EXAMINER<br>INITIAL |     | DOCUMENT NUMBER | DATE    | NAME       | PAGES, COLUMNS, LINES, WHERE<br>RELEVANT PASSAGES OR RELEVANT<br>FIGURES APPEAR |
|----------------------|-----|-----------------|---------|------------|---|
|                      | A14 | 09/393,652      | 9/10/99 | Srivastava |   |
|                      | A15 | 7,179,462 B2    | 2/20/07 | Srivastava |   |

**FOREIGN PATENT DOCUMENTS**

|  |  | FOREIGN PATENT<br>DOCUMENT<br>COUNTRY CODE, NUMBER,<br>KIND CODE (IF KNOWN) | DATE | NAME | PAGES, COLUMNS, LINES, WHERE<br>RELEVANT PASSAGES OR<br>RELEVANT FIGURES APPEAR | T |
|--|--|---|------|------|---|---|
|  |  |   |      |      |   |   |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials |      | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  | T |
|----------------------|------|--|---|
|                      | C115 | Abbas, Lichtman, and Pober, 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)  |   |
|                      | C116 | Janeway, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V, Sections 13-1 to 13-15)   |   |
|                      | C117 | Chandawarkar et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324 |   |
|                      | C118 | Steinman, L., 2001, "Myelin-specific CD8+ T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30                  |   |
|                      | C119 | SenGupta et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA Class I and Class II," J. Immunol. 173:1987-1993                        |   |
|                      | C120 | Srivastava et al., 1986, "Tumor rejection antigens of chemically induced sarcomas of inbred mice," Proc. Natl. Acad. Sci. U.S.A. 83:3407-3411                                  |   |
|                      | C121 | Rapley, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54   |   |
|                      | C122 | Costanzo, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7  |   |

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.